Introduction
============

Naringenin is chemically known as 5,7-dihydroxy-2-(4-hydroxyphenyl) chroman-4-one ([Fig. 1](#fig-1){ref-type="fig"}) and abundantly present in grapefruits and citrus fruits and some other food items ([@ref-27]). Since naringenin was identified from extracts of dormant peach flower buds by [@ref-15], growing attention has been paid to naringenin-mediated bioactivities. In the past decades, a great many studies have been reported that naringenin exhibits a wide range of pharmacological activities, including beneficial effects in liver diseases ([@ref-16]), antioxidative effect ([@ref-39]), immunomodulating activity ([@ref-24]), and antitumor activity ([@ref-1]; [@ref-13]; [@ref-22]; [@ref-23]; [@ref-26]; [@ref-30]; [@ref-38]). These findings suggest that naringenin appears to be full of therapeutic significance. Hence, it is important to explore the underlying mechanisms of its bioactivities and identify connectivity existing between gene and phenotype liaised by flavanone naringenin in publicly available data. Nevertheless, current knowledge about naringenin function and its mechanisms and targets is based on conventional experiments with high cost and long duration, which are far from integration and comprehension. Accordingly, appropriate and relevant approaches for systematic dissection of available published data are needed to generate authentic and rational lead.

![The structure of naringenin.](peerj-07-6611-g001){#fig-1}

Recently, various types of omics, which encompass genomics, proteomics, and other high-throughput sequencing technology, have been producing and accumulating massive data. Diverse computational approaches have been developed to mine and integrate these data in public databases, which provide researchers opportunities to conduct biomedical research, knowledge discovery, and innovative application ([@ref-21]). As for exploration of the relationship between naringenin-mediated proteins and their relevant phenotype, the network-based approach is considered to be a simple but effective solution, which may lie in the combination of DrugBank, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and the Database for Annotation, Visualization and Integrated Discovery (DAVID; [@ref-19]; [@ref-34]; [@ref-37]). DrugBank is a web-enabled tool that allows researchers to search and mine drug-primary targets information ([@ref-36]). Subsequently, STRING database could predict information for primary--secondary targets interaction in silico ([@ref-34]).

In this study, we employed DrugBank to widely study flavanone naringenin and obtain related direct protein targets (DPTs) information. The STRING database was then used to explore the interactions between DPTs and indirect protein targets (IPTs), and protein--protein interaction (PPI) network of naringenin-mediated proteins (including DPTs and IPTs) was subsequently constructed and visualized by Cytoscape based on interaction data obtained in STRING. Next, functions of all naringenin-mediated proteins were investigated through Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis by DAVID. Pivotal protein genes (*ESR1*, *PIK3CA*, *AKT1*, *MAPK1*) were identified among all naringenin-mediated proteins and investigated genomic alterations using cBioPortal database. In general, the results of this functional network analysis help to provide information for integratively understanding mechanisms of naringenin action, and the implications for the prevention and therapy of prostate cancer by naringenin.

Materials and methods
=====================

Search for direct protein targets of naringenin
-----------------------------------------------

The DrugBank database (<https://www.drugbank.ca>) is a web-based bioinformatic tool, including numerous drug information such as chemical structure, targets, transporters, biointeractions, and so on ([@ref-37], [@ref-36]). The comprehensive information could be used to facilitate construction of drug-target interactome in silico. Thus, the DrugBank database was employed to search for DPTs of naringenin. The analysis results were then used for further analysis.

Network visualization and KEGG pathway enrichment analysis
----------------------------------------------------------

Direct protein targets obtained from the DrugBank database were in turn subject to retrieval in the STRING database (<http://www.string-db.org/>), setting the minimum required interaction score as 0.5 and max number of interactors as 20. The IPTs of naringenin were generated after removing repetitive proteins. Then interactions of all naringenin-mediated proteins were analyzed by the STRING web server, and their PPI network was visualized using Cytoscape software (version 3.6.1) ([@ref-33]). Subsequently, all naringenin-mediated proteins were also carried on functional KEGG pathway enrichment analysis by DAVID with *p*-value \< 0.05.

Exploring cancer genomics data linked to naringenin by cBioPortal
-----------------------------------------------------------------

The cBioPortal for Cancer Genomics (<http://cbioportal.org>) is an open-access platform for cancer researchers to explore multidimensional cancer genomics data ([@ref-6]; [@ref-10]). Biologic insights and clinical applications could be understood using these rich genomic data. In this study, screened protein genes (*ESR1*, *PIK3CA*, *AKT1*, *MAPK1*) from the investigation above were subject to genetic alteration analysis in all prostate cancer studies available in cBioPortal databases. Then, the prostate cancer study with the highest genetic alteration was chosen to analyze the connectivity of the screened protein genes (*ESR1*, *PIK3CA*, *AKT1*, *MAPK1*). [@ref-10] study helped us to interpret the result of the query in cBioPortal.

Results
=======

Characterization of naringenin DPTs
-----------------------------------

Some small molecule chemical compounds can directly interact with proteins in organisms, which will result in alteration of the downstream pathway and various physiologic functions. In order to achieve DPTs of naringenin and relevant information, we entered Drugbank using naringenin as input. As a result, the output displayed DB03467 and total of eight primary DPTs. In the category of pharmacological activity, naringenin was classified as antiulcer agents, estrogen antagonists, BCRP/ABCG2 inhibitors, gastrointestinal agents, and hormone antagonists. Subsequent screening demonstrated seven DPTs belonging to human beings, which were presented in [Table 1](#table-1){ref-type="table"}, ESR1, AKR1C1, CYP1B1, KANSL3, SHBG, CYP19A1, and ESR2. In addition, interactions between naringenin and seven DPTs were analyzed and illustrated in [Fig. 2](#fig-2){ref-type="fig"}. It should be noted three direct target proteins (CYP19A1, SHBG, ESR2) showed a direct association with ESR1, suggesting that ESR1 played a critical role in targeted pathways controlled or mediated by naringenin.

![The interactions of naringenin and its DPTs.](peerj-07-6611-g002){#fig-2}
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###### Identification of direct protein targets of naringenin using DrugBank.

![](peerj-07-6611-g007)

  No.   Uniprot ID   Uniprot name                             Gene name
  ----- ------------ ---------------------------------------- -----------
  1     P03372       Estrogen receptor                        ESR1
  2     Q04828       Aldo-keto reductase family 1 member C1   AKR1C1
  3     Q16678       Cytochrome P450 1B1                      CYP1B1
  4     Q9P2N6       KAT8 regulatory NSL complex subunit 3    KANSL3
  5     P04278       Sex hormone-binding globulin             SHBG
  6     P11511       Aromatase                                CYP19A1
  7     Q92731       Estrogen receptor beta                   ESR2

Visualization and PPI network construction of naringenin-mediated proteins
--------------------------------------------------------------------------

In biological systems, physiologic functions rely on interactions among diverse proteins, which can be represented by a network consisting of nodes and edges. Thus, there should be of great importance to search for downstream targets of naringenin DPTs. To this end, STRING database was applied to identify DPTs-related proteins and the results were summarized in [Table S1](#supp-1){ref-type="supplementary-material"}. In general, total of 109 naringenin-mediated proteins ([Table S2](#supp-2){ref-type="supplementary-material"}) were generated including seven DPTs and 102 IPTs. Moreover, the interaction data of all naringenin-mediated proteins were obtained using STRING ([Table S3](#supp-3){ref-type="supplementary-material"}) and the PPI network were then visualized by Cytoscape 3.6.1 ([@ref-33]). As shown in [Fig. 3](#fig-3){ref-type="fig"}, there were 912 PPI pairs in the network of naringenin-mediated proteins. The nodes indicated proteins and the edges indicated the interactions between these proteins. Next, node degree was evaluated to investigate the centrality of proteins and represented by size, low values to the small size. Ranked by degree value from large to small, top 10 proteins were screened out and showed in [Table 2](#table-2){ref-type="table"}, including three DPTs (ESR1, CYP19A1, ESR2). These findings collectively indicated that biological effects mediated by naringenin are connected to ESR1.

![PPI network of naringenin-mediated proteins.\
The nodes indicate proteins and the edges indicate interaction between proteins. High node degree value was represented by big size and low node degree value was represented by small size.](peerj-07-6611-g003){#fig-3}
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###### The list of top 10 proteins ranked by degree value.

![](peerj-07-6611-g008)

  No.   Gene name   Node degree   No.   Gene name   Node degree
  ----- ----------- ------------- ----- ----------- -------------
  1     ESR1        51            6     HPGDS       38
  2     CYP19A1     48            7     ESR2        35
  3     HSD17B6     44            8     JUN         34
  4     CYP1A1      43            9     HSD3B2      34
  5     CYP3A4      38            10    UGT1A6      33

KEGG enrichment pathway analysis of naringenin-mediated proteins
----------------------------------------------------------------

As a collection of molecular interaction, reaction, and relation networks, KEGG pathways offer a good understanding of high-level functions and the biological system. Thus, we performed the KEGG pathway enrichment analysis using DAVID to assess the functional feature of naringenin-mediated proteins ([Table S4](#supp-4){ref-type="supplementary-material"}). As can be seen in [Table 3](#table-3){ref-type="table"}, the top 15 KEGG pathways linked to naringenin-mediated proteins were identified and included steroid hormone biosynthesis, metabolism of xenobiotics by cytochrome P450, chemical carcinogenesis, drug metabolism-cytochrome P450, retinol metabolism, pentose and glucuronate interconversions, ascorbate and aldarate metabolism, ovarian steroidogenesis, drug metabolism-other enzymes, porphyrin and chlorophyl metabolism, prolactin signaling pathway, thyroid hormone signaling pathway, estrogen signaling pathway, metabolic pathways, and prostate cancer. The broad grouping of functional enrichment analysis results indicated that naringenin-mediated proteins were mainly linked to (1) estrogen-related signaling pathways, (2) basal metabolism pathways, (3) cancer-related pathways. Given the importance of ESR1 in all naringenin-mediated proteins, emphasis of biological functions was directed to pathway possessing ESR1. Thus, three ESR1-related pathways were identified: prolactin signaling pathway, thyroid hormone signaling pathway, and estrogen signaling pathway. Besides, because anticarcinogenic properties of naringenin have been reported in diverse malignant tumors as mentioned above, prostate cancer pathway consisting of eight proteins was found: AKT1, MAPK1, IGF1R, AR, CCND1, INS, PIK3CA, IGF1. This result suggested that prostate cancer might be as a phenotype connected to naringenin-mediated proteins.

10.7717/peerj.6611/table-3

###### Top 15 enriched KEGG pathways identified using DAVID.

![](peerj-07-6611-g009)

  Pathway description                            Gene count   Gene                                                                                                                                                                                                                                                                                *p*-value
  ---------------------------------------------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Steroid hormone biosynthesis                   33           CYP3A4, HSD3B2, CYP3A5, HSD3B1, CYP1B1, HSD17B2, HSD17B1, CYP11B1, COMT, UGT1A7, AKR1C3, UGT1A6, UGT1A9, UGT1A3, UGT1A4, UGT2A1, HSD17B6, HSD17B3, SRD5A1, UGT2A3, SULT1E1, HSD17B7, AKR1C1, CYP19A1, HSD17B8, CYP1A1, UGT1A1, UGT1A10, UGT2B17, CYP17A1, UGT2B15, AKR1D1, UGT2B7   4.86*E*-49
  Metabolism of xenobiotics by cytochrome P450   26           GSTA1, CYP3A4, CYP3A5, CYP1B1, SULT2A1, CYP1A1, EPHX1, GSTT1, UGT1A1, DHDH, GSTM1, UGT1A7, UGT1A10, GSTM2, UGT1A6, UGT1A9, UGT2B17, GSTM3, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT2B7, AKR1C1, GSTP1                                                                           3.29*E*-31
  Chemical carcinogenesis                        24           GSTA1, CYP3A4, CYP3A5, CYP1B1, SULT2A1, CYP1A1, EPHX1, GSTT1, UGT1A1, UGT1A7, GSTM1, UGT1A10, UGT1A6, GSTM2, UGT1A9, UGT2B17, GSTM3, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT2B7, GSTP1                                                                                         8.08*E*-27
  Drug metabolism-cytochrome P450                20           GSTA1, CYP3A4, CYP3A5, GSTT1, UGT1A1, UGT1A7, GSTM1, UGT1A10, UGT1A6, GSTM2, UGT1A9, UGT2B17, GSTM3, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, GSTP1, UGT2B7                                                                                                                         6.4*E*-22
  Retinol metabolism                             16           CYP3A4, CYP3A5, CYP1A1, UGT1A1, UGT1A7, UGT1A6, UGT1A10, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, HSD17B6, UGT2A3, UGT2B15, UGT2B7                                                                                                                                                  3.57E-16
  Pentose and glucuronate interconversions       13           UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, DHDH, UGT2B7                                                                                                                                                                             1.02*E*-15
  Ascorbate and aldarate metabolism              12           UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, UGT2B7                                                                                                                                                                                   3.81*E*-15
  Ovarian steroidogenesis                        14           AKR1C3, HSD3B2, IGF1R, CYP17A1, HSD3B1, CYP1B1, CYP1A1, HSD17B2, INS, HSD17B1, IGF1, GNAS, HSD17B7, CYP19A1                                                                                                                                                                         6.86*E*-15
  Drug metabolism-other enzymes                  13           CYP3A4, UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, UGT2B7                                                                                                                                                                           1.01*E*-13
  Porphyrin and chlorophyl metabolism            12           UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, UGT2B7                                                                                                                                                                                   1.10*E*-12
  Prolactin signaling pathway                    12           AKT1, MAPK1, FOS, CYP17A1, CCND1, INS, ESR1, PIK3CA, MAPK11, ESR2, PRL, SRC                                                                                                                                                                                                         4.99*E*-10
  Thyroid hormone signaling pathway              12           AKT1, MAPK1, NCOA1, CCND1, NCOA2, NCOA3, ESR1, PIK3CA, NCOR1, MYC, SRC, MED1                                                                                                                                                                                                        9.09*E*-08
  Estrogen signaling pathway                     10           AKT1, MAPK1, FOS, JUN, ESR1, PIK3CA, NOS3, GNAS, ESR2, SRC                                                                                                                                                                                                                          2.26*E*-06
  Metabolic pathways                             32           CYP3A4, HSD3B2, CYP3A5, HSD3B1, HSD17B2, HSD17B1, CYP11B1, COMT, AKR1C3, UGT1A7, UGT1A6, UGT1A9, POLE4, UGT1A3, UGT1A4, UGT2A1, HSD17B6, HSD17B3, NOS3, UGT2A3, HPGDS, HSD17B7, CYP19A1, HSD17B8, CYP1A1, UGT1A1, UGT1A10, UGT2B17, CYP17A1, UGT2B15, AKR1D1, UGT2B7                1.18*E*-05
  Prostate cancer                                8            AKT1, MAPK1, IGF1R, AR, CCND1, INS, PIK3CA, IGF1                                                                                                                                                                                                                                    7.70*E*-05

Genetic alterations connected with naringenin-mediated protein genes in prostate cancer
---------------------------------------------------------------------------------------

Previous functional enrichment analysis uncovered the link between naringenin-mediated proteins and prostate cancer pathway. Further exploration was needed to validate this link. Since ESR1 enjoyed the highest centrality among all naringenin-mediated proteins as proved previously, and because three overlapping proteins (PIK3CA, AKT1, MAPK1) associated with ESR1 were found to be connected to prostate cancer pathway as well, the genomic alteration of these four protein genes (*ESR1*, *PIK3CA, AKT1*, *MAPK1*) were checked in prostate cancer using cBioPortal. Among 16 prostate cancer studies ([@ref-2]; [@ref-3]; [@ref-4]; [@ref-8]; [@ref-11]; [@ref-12]; [@ref-17]; [@ref-20]; [@ref-5]; [@ref-29]; [@ref-35]), gene alterations ranged from 0% to 31.58% as displayed in [Fig. 4](#fig-4){ref-type="fig"}. Because of the most pronounced genetic alterations among all prostate cancer studies available in cBioPortal, the NEPC study ([@ref-4]) was selected individually to view relevant genomic changes of four genes. A concise and compact summary of alterations in three queried genes (*ESR1*, *PIK3CA*, *AKT1*, *MAPK1*) was shown in [Fig. 5](#fig-5){ref-type="fig"} using OncoPrint. The results presented that most gene alterations belonged to amplification. Additional mutual exclusivity analysis indicated that every gene pair exhibited significant (*p*-value \< 0.05) co-occurrence in prostate samples in the study of NEPC ([Table 4](#table-4){ref-type="table"}). The co-occurrence of *ESR1* and other three genes revealed a central axis function for *ESR1* under naringenin control.

![Overview of changes on *ESR1*, *PIK3CA*, *AKT1*, and *MAPK1* genes in genomics data sets available in 16 different prostate cancer studies.](peerj-07-6611-g004){#fig-4}

![A visual summary of alteration across a set of prostate samples (data taken from the NEPC studies, Nat Med 2016) ([@ref-4]) based on a query of four genes *ESR1*, *PIK3CA*, *AKT1*, and *MAPK1*.\
Different genomic alterations are summarized and color coded presented by % changes in particular affected genes in individual tumor samples. Each row represents a gene, and each column represents a tumor sample.](peerj-07-6611-g005){#fig-5}
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###### Mutual exclusivity analysis of four selected genes (*ESR1*, *AKT1*, *PIK3CA*, *MAPK1*) in NEPC study.

![](peerj-07-6611-g010)

  Gene A   Gene B   *p*-value   Log2 odds ratio   Association
  -------- -------- ----------- ----------------- -------------------------------
  ESR1     AKT1     \<0.001     \>3               Tendency toward co-occurrence
  ESR1     PIK3CA   \<0.001     \>3               Tendency toward co-occurrence
  ESR1     MAPK1    0.003       \>3               Tendency toward co-occurrence
  PIK3CA   AKT1     \<0.001     2.733             Tendency toward co-occurrence
  AKT1     MAPK1    0.002       \>3               Tendency toward co-occurrence
  PIK3CA   MAPK1    0.005       \>3               Tendency toward co-occurrence

Subsequently, the Network tab embedded in cBioportal was exploited to explore the interactive relationship between four selected genes and genes that were altered in NEPC prostate cancer study. A query of *ESR1*, *PIK3CA*, *AKT1*, and *MAPK1* automatically generated a network containing 50 neighbor genes of four query genes, and legends were available to explain network symbols ([Fig. 6A](#fig-6){ref-type="fig"}). To manage network complexity, we filtered neighbors by 45% alteration, such that only *AR* gene with the highest alteration frequency remained in addition to four query genes ([Fig. 6B](#fig-6){ref-type="fig"}). The pruned network revealed the potential interactions between naringenin-mediated genes and altered genes in prostate cancer samples. Moreover, specific cancer drugs acting on ESR1, PIK3CA, AKT1, and MAPK1 were displayed in [Fig. 5](#fig-5){ref-type="fig"}. ESR1 was the main target of most FDA approved drugs (represented by yellow hexagon) in the network, providing a molecular basis for potential clinical applications of naringenin to treat prostate cancer targeting ESR1.

![A visual display of the gene network connected to ESR1/PIK3CA/AKT1/MAPK1 in prostate adenocarcinoma (based on the NEPC study, Nat Med 2016) ([@ref-4]).\
(A) Cross-cancer alteration summary for ESR1/PIK3CA/AKT1/MAPK1 mined from the cBioPortal for Cancer Genomics. Multidimensional genomic details are shown for seed genes *ESR1*, *PIK3CA*, *AKT1*, and *MAPK1*. A darker shade of red indicates increased frequency of alteration in prostate cancer. (B) Neighboring genes connected to the four query genes, filtered by alterations (45%).](peerj-07-6611-g006){#fig-6}

Discussion
==========

Since naringenin was reported by [@ref-15], there has been an increasing number of publications on naringenin and more than 2,400 publications have accumulated on PubMed to date. A wide range of biological and cellular activities have been reported for naringenin, including relevant targets and biological pathways. These findings suggested that naringenin connected with a plethora of diseases and possessed a fascinating nature. However, there are still barriers to systematically understand how naringenin facilitates its wide range of beneficial effects. As such, a bridge between naringenin and its direct and indirect targets needs to be established. To this end, functional network analysis ([@ref-18]; [@ref-31]) with new analytical ways or platforms is introduced in this study and enables to explore naringenin-mediated proteins, thereby elucidating connectivity between protein genes and phenotype.

In our study, functional network analysis was performed by using a series of web-based bioinformatic tools. Firstly, the feasibility of analysis for connectivity between naringenin targets and its phenotypes was demonstrated by using DrugBank and STRING, resulting in the identification of seven DPTs (ESR1, AKR1C1, CYP1B1, KANSL3, SHBG, CYP19A1, ESR2), 102 IPTs ([Table S2](#supp-2){ref-type="supplementary-material"}). Secondly, the KEGG enrichment analysis conducted by DAVID identified three ESR1-related signaling pathways and prostate cancer pathway, which were significantly altered by naringenin-mediated proteins. As supporting evidence, previous studies have observed that naringenin exhibits antineoplastic property against most solid tumors including breast and colorectal ([@ref-1]), bladder ([@ref-22]), prostate ([@ref-23]), and so on. Thus, the association between prostate cancer and the beneficial effects exerted by naringenin in cancer was then explored and assessed by the genetic alternations in four protein genes (*ESR1*, *PIK3CA*, *AKT1*, and *MAPK1*) which were revealed by naringenin associated three ESR1-related signaling pathways and prostate cancer pathway. Most of the genetic alterations in *ESR1*, *PIK3CA*, *AKT1*, and *MAPK1* were amplifications, suggesting an excess expression in prostate cancer. Consistent with our study, [@ref-9] pointed out it that the genetic polymorphisms in *ESR1* gene could cause transcription change, resulting in the influence the risk of prostate cancer. PI3K/AKT pathway including PIK3CA and AKT1 is a well-known pathway involved in the regulation of cell proliferation, metastasis, and apoptosis ([@ref-25]). Recent research even found that *PIK3CA* amplification had a correlation with poor survival of patients with prostatic carcinoma ([@ref-28]). To the present, *MAPK1* is a famous oncogene, acting as a signal transduction node of various upstream signals such as proliferation, inhibition of apoptosis, and so on ([@ref-7]). Moreover, the mutual exclusivity analysis discovered a tendency toward co-occurrence between *ESR1* and three overlapping genes. Hence, the results were in good agreement with it that *ESR1* acted as a major driver of anti-carcinogenic efficiency in prostate cancer. In addition, *PIK3CA*, *AKT1*, and *MAPK1* directly interacted with *AR* ([Fig. 6B](#fig-6){ref-type="fig"}), which was a naringenin-mediated protein gene as well and participated in prostate cancer pathway. As support, AR has been reported to be crucial to prostate cell growth and development ([@ref-14]). Therefore, a hypothesis is currently proposed that naringenin acts through a series of genes (*ESR1*, *PIK3CA*, *AKT1*, *MAPK1*, and *AR*) to control prostate cancer cell proliferation.

Prostate cancer is the most common malignancy in male cancer patients with high mortality, accounting for 23% of all new cancer cases worldwide ([@ref-32]). The gene-phenotype connectivity liaised by naringenin revealed that the regulation of ESR1 by naringenin might be a major driver for the chemoprotective salutary effects on prostate adenocarcinoma. The candidate genes identified may facilitate the comprehension of genomic results and be considered to provide information useful for guiding further research of naringenin and future drug development. However, some challenges of this analysis remain to be investigated and solved: (1) whether the connectivity existing between naringenin and prostate cancer can extend to other malignant tumors is still essential to explore; (2) the role of genes under naringenin control detected in this research must be verified in prostate cancer.

Conclusions
===========

In conclusion, functional network analysis based on a series of online tools including DrugBank, STRING, DAVID, and cBioPortal has been applied to mine and integrate knowledge of naringenin biological action. The retrieval of publicly available computational databases unraveled the connectivity existing between naringenin and prostate cancer. A hypothesis currently being considered is that naringenin could regulate prostate cancer via ESR1 signaling axis. Naringenin might be promising as an alternative chemotherapy or chemoprevention for prostate cancer. Overall, this functional network analysis provided a reasonable hypothesis and assisted in the acceleration of naringenin biology research.
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